Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDENTIFY: Doravirine and Tenofovir PK with Hormonal Therapy
NCT04283656Phase 1Completed
- Sponsor
- Thomas Jefferson University
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of doravirine and tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Thomas Jefferson University. Primary endpoints: Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity, Doravirine Maximum Concentration and 4 more. Started Jan 2022; status: completed.
02
Drugs
doravirinetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04283656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04283656.